Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 4/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23378251 | 0.79 | CA12 (0.33) | BTN3A1CA12 | |
| SCHEMBL23378043 | 0.72 | CA14 (0.31) | CA14 | |
| SCHEMBL15760474 | 0.70 | LPAR3 (0.41) | BTN3A1PRKCAPOLBGAANPSR1 | |
| SCHEMBL4156487 | 0.69 | POLB (0.43) | BTN3A1PRKCAPOLBGAANPSR1 | |
| SCHEMBL18512735 | 0.69 | BTN3A1 (0.33) | BTN3A1CA12 | |
| SCHEMBL4258156 | 0.69 | POLB (0.48) | BTN3A1PRKCAPOLBGAANPSR1 | |
| SCHEMBL19397155 | 0.68 | BTN3A1 (0.35) | BTN3A1CA12TSHR | |
| SCHEMBL19235959 | 0.68 | BTN3A1 (0.33) | BTN3A1PRKCA | |
| SCHEMBL22820231 | 0.67 | CA14 (0.46) | BTN3A1CA14CA12MEN1TSHR | |
| SCHEMBL18512758 | 0.67 | CA12 (0.33) | CA14CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210155644-A1 | CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2021-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210155644-A1 | CYCLOPENTENYL PURINE DERIVATIVE OR SALT THEREOF | SLC28A1, SLC20A1, NOX1 | BTN3A1 3970/4885CA14 2039/4885PRKCA 4322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.